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Murine pluripotent stem cells can exist in two func-
tionally distinct states, LIF-dependent embryonic
stem cells (ESCs) and bFGF-dependent epiblast
stem cells (EpiSCs). However, human pluripotent
cells so far seemed to assume only an epiblast-like
state. Here we demonstrate that human iPSC reprog-
ramming in the presence of LIF yields human stem
cells that display morphological, molecular, and
functional properties of murine ESCs. We termed
these hLR5 iPSCs because they require the expres-
sion of five ectopic reprogramming factors, Oct4,
Sox2, Klf4, cMyc, and Nanog, to maintain this more
naive state. The cells are ‘‘metastable’’ and upon
ectopic factor withdrawal they revert to standard
human iPSCs. Finally, we demonstrate that the
hLR5 state facilitates gene targeting, and as such
provides a powerful tool for the generation of re-
combinant human pluripotent stem cell lines.
INTRODUCTION
Embryonic stem cells (ESCs) were first derived in 1981 from
the inner cell mass (ICM) of murine preimplantation blastocyst
embryos (Evans and Kaufman, 1981; Martin, 1981). ESCs
are pluripotent, meaning they are able to expand indefinitely
in vitro while retaining the capacity to generate derivatives of
all three germ layers both in vitro and in vivo. The discovery of
murine ES cells (mESCs) was a major breakthrough in develop-
mental biology, because it enabled the study of mammalian
gene function in vivo, via transgenic and knockout technologies.
The subsequent derivation of human ES cells (hESCs) raised the
expectation that these cells would similarly revolutionize ourinsights into human development and disease. Unfortunately,
human pluripotent stem cells are remarkably resilient to nonviral
genetic manipulation and to date only a handful of human
knockin or knockout cell lines exist. As a result, the application
of human pluripotent stem cells has been more limited than
previously anticipated.
Although both human and murine ESCs are derived from blas-
tocyst-stage embryos, they demonstrate profound differences
(Thomson et al., 1998). Murine ESCs grow in three-dimensional,
tightly packed colonies with a population doubling time of
approximately 16 hr and their maintenance is dependent on
LIF and BMP4 growth factor signaling (Smith et al., 1988; Xu
et al., 2005; Ying et al., 2003). In contrast, human ESCs form flat-
tened two-dimensional colonies and are maintained in a bFGF
and Activin A/TGF-b signaling-dependent manner (Thomson
et al., 1998). hESCs proliferate slowly, with a population doubling
time averaging 36 hr. Epigenetically, human and murine ESCs
display a different X chromosome inactivation pattern
and promoter occupancy by pluripotency transcription factors
(Boyer et al., 2005; Silva et al., 2008; Tesar et al., 2007). In addi-
tion, hESCs are passaged as small clumps of cells, and most
hESC lines cannot be passaged as single cells by trypsin digest.
The inability of hESC lines to grow from single cells greatly
impedes genetic modification of these cells, because the intro-
duction of transgenes is typically followed by clonal selection.
Two reports on the derivation of murine epiblast stem cells
(EpiSCs) recently provided a new perspective on the nature of
human ESCs (Brons et al., 2007; Tesar et al., 2007). EpiSCs
are derived from postimplantation murine epiblast embryos
under culture conditions similar to hESC culture conditions.
EpiSCs display many of the characteristics of human ESCs
including their dependence on bFGF/Activin A signaling, their
flattened colony morphology, their slower proliferation rate com-
pared to murine ESCs, their X-inactivation status, and their
requirement to be passaged as small clumps of cells (Brons
et al., 2007; Tesar et al., 2007).Cell Stem Cell 6, 535–546, June 4, 2010 ª2010 Elsevier Inc. 535
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murine ESCs and EpiSCs appear to be largely determined by
the growth factor conditions under which these cell types are
derived and maintained. Indeed, recent work from our group
demonstrates that culture growth factor conditions play a criti-
cal role in defining the pluripotent stem cell state (Chou et al.,
2008). Intriguingly, although pluripotent stem cells can be stably
derived and propagated frommultiple species in an epiblast-like
state, including the rat and ‘‘nonpermissive’’ mouse strains, the
LIF-dependent pluripotent state appears to be unstable in these
species (Buehr et al., 2008; Hanna et al., 2009; Li et al., 2009;
Liao et al., 2009). However, the LIF-dependent pluripotent state
can be stabilized through the constitutive ectopic expression of
one or more of the reprogramming factors (Oct4, Sox2, Klf4,
cMyc), which induce the generation of induced pluripotent
stem cells (iPSCs) from somatic cells (Takahashi et al., 2007;
Takahashi and Yamanaka, 2006). In the nonpermissive NOD
mouse strain, for example, the constitutive ectopic expression
of either Klf4 or cMyc is sufficient to allow the derivation of
ES-like cells from blastocyst embryos (Hanna et al., 2009). Small
molecule inhibitors of glycogen synthase kinase 3 beta (GSK3b)
and the mitogen-activated protein kinase (MAPK) signaling
pathway can replace some of the reprogramming factors during
iPSC generation (Li and Ding, 2009). These inhibitors can simi-
larly stabilize the LIF-dependent mES-like pluripotent stem cell
state from both the nonpermissive NOD mouse strain and the
rat (Buehr et al., 2008; Hanna et al., 2009; Li et al., 2009; Liao
et al., 2009). Thus, it appears that the LIF-dependent pluripotent
state is metastable in these species, meaning that it is depen-
dent on either the constitutive expression of ectopic reprogram-
ming factors or the continued inhibition of GSK3b and/or the
MAPK signaling pathways.
Although distinct pluripotent stem cell states are known to
exist in mouse and rat, they have thus far not been described
for human stem cells. A recent report demonstrates that stable
human iPS cells (hiPSCs) can be derived in the presence of LIF
and inhibitors of GSK3b and the TGF-b and MEK/ERK signaling
pathways (Li et al., 2009). However, these cells appear to be
molecularly identical to conventional hiPSCs. We used hiPSC
derivation as a tool to investigate the influence of growth factor
signaling on the human stem cell pluripotent state. Here we
demonstrate the derivation of human cell lines that display
many characteristics of murine ESCs including a dome-shaped
colony morphology, the ability to be propagated by trypsin
digest and to clonally grow from single cells, and the activation
of LIF downstream signaling pathways. We demonstrate that in
this state, the human cells aremore amenable to the introduction
of transgenes and allow homologous recombination-mediated
gene targeting. The LIF state is metastable, as indicated by the
fact that it depends on the constitutive expression of ectopic re-
programming factors. Yet a combination of growth factors and
inhibition of MEK-kinase signaling allows the conversion of the
human LIF-iPSCs to a stable, pluripotent human iPSC state.
Our findings support the idea that, analogous to mouse
strains and the rat, human iPSCs adopt murine ESC proper-
ties, when the cells are derived in the presence of LIF and
ectopic reprogramming factors. Importantly, this novel state
facilitates homologous recombination-mediated gene targeting
in human stem cells. As such, the intermediate iPSC state536 Cell Stem Cell 6, 535–546, June 4, 2010 ª2010 Elsevier Inc.described here can be a useful tool in research and future
cell therapies.
RESULTS
Derivation of Metastable Human iPSC Lines with Murine
ESC Characteristics
We used the recently reported induced pluripotent stem cell
(iPSC) strategy to explore the possibility of deriving human iPSCs
in the presence of LIF. The five reprogramming factors OCT4,
SOX2, NANOG, c-MYC, and KLF4 were expressed in human
fibroblast via a recently reported doxycyline-inducible lentiviral
system (Figure 1A; Maherali et al., 2008). Fibroblasts were
reprogrammed either directly from the primary fibroblasts or
from so-called secondary fibroblasts, derived from differentiated
‘‘primary’’ hiPSCs (Maherali et al., 2008). With either approach,
reprogramming of human fibroblasts in the presence of LIF
resulted in the formation of two types of colonies: transient, irreg-
ularly shaped colonies that deteriorated a few days after their
first appearance (Figure S1A available online) and smaller, tightly
packed colonies (Figure S1B). We picked individual colonies of
the latter for further clonal analysis. These clones displayed the
hallmark, tightly packed, bright, dome-shaped morphology of
mESCs (Figure 1B), contrasting the flattened two-dimensional
colony morphology of hESCs (Figure 1B). We designated these
cells human LR5-iPSCs (hLR5) (human LIF + the constitutive
expression of 5 reprogramming factors).
Next we investigated the cell surface marker profile of the
hLR5 cells. Murine and human pluripotent stem cells express a
mutually exclusive complement of cell surface markers. SSEA1
is expressed on undifferentiated murine pluripotent stem cells
whereas human pluripotent stem cells express the SSEA3,
SSEA4, TRA-1-81, and TRA-1-60 cell surface markers. Flow
cytometry analysis of the hLR5 cells revealed a marker profile
that resembles the surface marker profile of mESCs (Figure 1C).
hLR5 cells do not express the TRA-1-81 cell surface marker
(Figure 1C) but demonstrated high expression of the SSEA1
cell surface marker, which is typically expressed on murine
pluripotent stem cells (Figure 1C). A fourth clone, which was
derived through direct reprogramming of human fibroblasts
from a different genetic background, also lacked TRA-1-81
expression but expressed low SSEA1 levels, suggesting that
the level of SSEA1 expression is heterogeneous between hLR5
clones of different genetic backgrounds. In addition to the
general lack of TRA-1-81 expression, hLR5 cells also do not
express SSEA3, SSEA4, and TRA-1-60, as tested by flow cytom-
etry and immunohistochemistry (not shown). Unlike hESCs, the
hLR5 cells can be propagated by trypsin digest. This result
suggested that similar to mESCs, hLR5 cells are tolerant to
passaging as single cells. Indeed, upon single cell sorting of
hLR5 cells into 96-well plates, hLR5 clones re-emerged in
approximately 22% of the wells (n = 10), similar to the efficiency
of single-cell sorted mESCs (30%), whereas upon single-cell
sorting of the trypsin-adapted HUES3 hESC line (Cowan et al.,
2004), no colonies re-emerged (n = 10). In addition, the hLR5
cells displayed a much higher proliferation rate than human
ESCs or iPSCs, with a cell doubling time of approximately
22 hr (Figure 1D). The hLR5 proliferation rate is close to the
















































































































































































Figure 1. A Metastable Human iPSC State with Murine ESC Properties
(A) Schematic representation of the used strategy. Doxycycline-inducible lentiviral vectors were added either as individual vectors (Maherali et al., 2008) or the
polycystronic human STEMCCA virus (Sommer et al., 2009) and inducible NANOG as indicated in the text.
(B) Colony morphology of hLR5 cells (left), murine ESCs (middle), and human ESCs. See also Figure S1.
(C) FACS analysis of cell surface marker expression on hLR5 cells, murine ESCs, and human iPSCs. Black lines, cell surface marker with the indicated primary
antibody; grey line, no primary antibody control.
(D) Growth curve of hLR5 cells, mESCs, and hESCs over a period of 12 days. Cumulative cell number is plotted against days (n = 3, SD).
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Naive Human Stem Cells with Murine ESC-like Propertiesmuch higher than the proliferation rate of hESCs or hiPSCs
(doubling time 36 hr).
Activation of the JAK-STAT Pathway and Downstream
Target Genes in hLR5 Cells
The growth factor environment is known to be an important
determinant of the stem cell pluripotent state (Brons et al.,
2007; Chou et al., 2008; Tesar et al., 2007). In mESCs, LIF acti-
vates the JAK/STAT3 and the RAS/MEK/MAPK signaling path-
ways, which have opposing roles in mESC maintenance anddifferentiation. Activation of the JAK-Stat3 signaling pathway
has been shown to be important for long-term self-renewal of
mESCs, whereas the RAS/MAPK pathway drives mESC differ-
entiation. Indeed, pharmacological inhibitors of the RAS/MEK/
MAPK pathway have been shown to enhance mESC self-
renewal and in combination with inhibitors of GSK3b allow
growth factor-independent maintenance of pluripotent stem
cells (Ying et al., 2008). hLR5 cells display many characteristics
of murine ESCs, so we investigated the effect of LIF and its
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Figure 2. LIF Responsiveness of hLR5 Cells
(A) Western blot analysis of STAT3 phosphorylation in two independent hLR5 clones, with or without LIF stimulation as indicated.
(B) Immunostaining of STAT3 subcellular localization in hLR5 cells before (top) or after (bottom) LIF stimulation. Note the translocation of STAT3 from the cyto-
plasm (top) to the nucleus (bottom). Cell nuclei were visualized with DAPI.
(C) Gene expression analysis of downstream target genes of the JAK/STAT signaling pathway in three hLR5 clones as well as human ESC lines and conventional
human iPSC lines.
(D) Flow cytometry analysis of SSEA1 surface marker on hLR5 cells upon LIF removal. Red lines, LIF control; blue line, LIF substitution with bFGF; green lines, no
added growth factor.
(E) Colony morphology of the hLR5 cells before (top) and after LIF substitution with bFGF.
(F) Flow cytometry analysis of SSEA1 cell surface marker expression on hLR5 cells in the presence of small molecule inhibitors. hLR5 cells were maintained
in hLR5 media for 1 week in the presence of inhibitors. Grey shaded area, Jak inhibitor; colored lines, MEK inhibitors (PD9805, PD184352, and PD0325901,
as indicated); blue line, no inhibitor control.
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stimulated in hLR5 cells in a LIF-dependent manner. Upon LIF
activation of the JAK-STAT signaling cascade, STAT3 translo-
cates from the cytosol to the nucleus and directly activates
downstream target genes. Immunofluorescence staining of
STAT3 in hLR5 cells revealed nuclear translocation in response
to LIF stimulation (Figure 2B). This translocation results in activa-
tion of STAT3 downstream target genes, including STAT3 itself
as well as SOCS3 and the LIF receptor, indicating that this
pathway is functionally active in response to LIF stimulation of
the hLR5 cells (Figure 2C).538 Cell Stem Cell 6, 535–546, June 4, 2010 ª2010 Elsevier Inc.Upon removal or substitution of LIF from the hLR5 culture
media, SSEA1 expression waned (Figure 2D). In addition, we
noticed a change in colony morphology (Figure 2E). Next we
used specific inhibitors of JAK/STAT signaling or the MAPK/
MEK signaling pathway to examine the roles of these pathways
in hLR5 cells. SSEA1 cell surfacemarker expression was used as
a readout. As shown in Figure 2F, inhibition of the JAK/STAT3
pathway resulted in a marked decrease of SSEA1 on hLR5 cells
(Jak-inhibitor I [0.6 mM], gray shaded area), whereas specific
inhibition of the MEK/ERK1/ERK2 pathway did not affect



























































































































































































































Figure 3. The hLR5 State Depends on Ectopic Pluripotency Factors but Is Poised for Reactivation of Endogenous Pluripotency Genes
(A) Ectopic factor dependence of hLR5 cells. Upon doxycycline withdrawal, hLR5 colony morphology is lost and cells adopt a fibroblast-like appearance. Days of
differentiation are indicated.
(B) Quantitative RT-PCR analysis of the expression of reprogramming factors used for the derivation and maintenance of hLR5 cells. Left panel: expression of
endogenous genes. Right panel: expression of the doxycyclin-inducible ectopic reprogramming factors. Human ESC strains (H9, HUES3, HUES14) and human
iPSC strains (hiPS1, hiPS2) were used as controls. Color coding of the genes is indicated (n = 3, SD).
(C) ChIP-qPCR analysis of the presence of histone 3 lysine 4 (H3K4, green bars) marks and histone 3 lysine 27 (H3K27, red bars) marks at the promoter regions of
the pluripotency genes SOX2, DNMT3b, and SALL4 as indicated in hLR5 cells (n = 3, SD). See Table S1 for primers.
(D) ChIP-qPCR analysis of the presence of histone 3 lysine 4 (H3K4, green bars) marks and histone 3 lysine 27 (H3K27, red bars) marks at the promoter regions of
the pluripotency genes OCT4, NANOG, and REX1 as indicated in hLR5 cells (n = 3, SD).
(E) DNA methylation analysis of two CpG islands in the OCT4 promoter as indicated in the schematic of the OCT4 promoter region. Open circles indicate unme-
thylated and filled circles indicate methylated CpG dinucleotides. Shown are representative sequenced clones from BJ fibroblasts, human iPSCs, and two inde-
pendent clonal hLR5 cell lines. The percentage of CpG methylation at each CpG island in the respective cell lines is indicated. TSS, transcription start site.
(F) Schematic representation of the generation of hLR5 cells in the absence (top, I) or presence (bottom, II) ofNANOG. Although in the absence ofNANOG expres-
sion traditional hiPSCs can be derived, no hLR5-like colonies form. Addition of ectopic NANOG results in the formation of hLR5 colonies. See also Figure S2.
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Naive Human Stem Cells with Murine ESC-like Properties[0.8 mM], and PD0325901 [1 mM], colored lines). Together these
results indicate that LIF stimulation of hLR5 cells results in acti-
vation of the JAK-STAT3 signaling cascade and upregulation
of downstream target genes whereas LIF withdrawal results in
changes in hLR5 colony phenotype. However, LIF withdrawal
does not result in hLR5 differentiation, perhaps because of the
persistent doxycyclin-induced ectopic expression of reprogram-
ming factors.
The hLR5 State Requires Continued Ectopic Expression
of Five Reprogramming Factors
Next we examined whether hLR5 cells could be stably propa-
gated in the absence of ectopic reprogramming factors. As
shown in Figure 3A, doxycycline withdrawal resulted in the rapid
loss of hLR5 colony morphology, with all cells adopting a fibro-
blast-like appearance within 3 days. A similar dependence wasfound for rat iPSCs (Liao et al., 2009) and for iPSCs from the
nonpermissive NOD mouse strain (Hanna et al., 2009). The
need for ectopic reprogramming factors suggested that in
hLR5 cells, the endogenous pluripotency genes have not yet
been fully activated. Q-PCR analysis of the expression of endog-
enous and ectopic pluripotency factors revealed that hLR5 cells
fail to reactivate endogenous OCT4 and NANOG expression,
while the expression of endogenous SOX2 and c-MYC are low
(Figure 3B). Endogenous KLF4 was expressed at similar levels
in hLR5 cells and human ESCs or iPSCs.
We then analyzed the presence of activating and silencing
histone marks at the promoter regions of critical regulators of
pluripotency. By using chromatin immunoprecipitation (ChIP)
and Q-PCR, we tested the presence of two histone marks:
histone 3 lysine 4-trimethylation (H3K4me3), a histone mark that
activates transcription (Pray-Grant et al., 2005; Santos-RosaCell Stem Cell 6, 535–546, June 4, 2010 ª2010 Elsevier Inc. 539
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Naive Human Stem Cells with Murine ESC-like Propertieset al., 2003; Sims et al., 2005; Wysocka et al., 2005), and histone
3-lysine 27-trimethylation (H3K27me3), which promotes stable
transcriptional repression (Francis et al., 2004; Ringrose et al.,
2004). Unexpectedly, ChIP-qPCR analysis revealed the pres-
ence of both marks at the promoter regions of SOX2, DNMT3b,
and SALL4 (Figure 3C). The H3K4 and H3K27methylation marks
are simultaneously present in so-called bivalent domains, which
in ESCs are often found at promoters of important transcriptional
regulators of development (Bernstein et al., 2006). Bivalent
domains result in transcriptional repression, but lead to a
‘‘poised’’ state that allows rapid activation or permanent repres-
sion by removing either one of the opposing histonemarks and is
consistent with the low-level endogenous expression of these
genes in hLR5 cells (Figure 3B).
ChIP-qPCR analysis of theH3K4me3 andH3K27me3marks at
the OCT4, NANOG, and REX1 promoters revealed the presence
of the repressive H3K27me3 mark in the hLR5 cells, corrobo-
rating the absence of endogenous expression of these genes
(Figure 3D). In somatic cells, OCT4 and NANOG are silenced
through additional epigenetic mechanisms including DNA
methylation, which is thought to be a permanent transcriptional
barrier. Indeed, DNAmethylation has been shown to be a limiting
step during iPSC reprogramming, and inhibition of DNA methyl-
ation can complete the reprogramming of partially reprog-
rammed iPSCs (Mikkelsen et al., 2008). Bisulfite sequencing
showed that, unexpectedly, the OCT4 promoter regions are
hypomethylated in the hLR5 cells as compared to the parental
BJ fibroblasts (Figure 3E).
Together, these results suggest that hLR5 cells exist in
a poised state of near pluripotency, in which some pluripotency
genes, including SOX2, DNMT3b, and SALL4, are in a bivalent
histone methylation state, whereas others, such as OCT4,
NANOG, and REX1, still carry the transcriptionally repressive
H3K27 methylation mark, but already display hypomethylation
at the OCT4 promoter region.
Surprisingly, in addition to the four common reprogramming
factors, ectopic expression of NANOG is also required for the
maintenance of the hLR5 state. By using the ‘‘secondary fibro-
blasts,’’ we analyzed hLR5 derivation in the presence or absence
of ectopic NANOG expression (Figure 3F). iPSC reprogramming
was induced with doxycycline via either conventional hESC
medium (with bFGF) or in hLR5 conditions (LIF). Whereas in
the presence of bFGF hiPSC colonies formed with or without
ectopic NANOG (Figures 3F, part I), under hLR5 culture condi-
tions colony formation is dependent on ectopic NANOG expres-
sion (Figure 3F, part II), demonstrating that NANOG is required
for the de novo derivation of hLR5 cells. In addition, we explored
the effect of ectopic NANOG expression when reactivating
reprogramming factors in existing hiPSCs in hLR5 medium. By
using hiPSCs derived with the STEMCCA lentivirus (Sommer
et al., 2009), we induced ectopic factor expression in the pres-
ence of human LIF with or without ectopic NANOG expression
(Figure S2A). In the presence of NANOG expression, colonies
appeared after 2–3 passages that showed the typical hLR5
morphology (Figure S2B, left), whereas without ectopic NANOG
expression, hiPSC colony morphology rapidly deteriorated in
hLR5 conditions (Figure S2B, right). However, hLR5 cell cultures
directly derived from hiPSCs remained heterogeneous, indi-
cating that direct conversion of hiPSCs into hLR5 cells was540 Cell Stem Cell 6, 535–546, June 4, 2010 ª2010 Elsevier Inc.incomplete and may require prolonged passaging and/or selec-
tion. Indeed, in similar manner, the conversion of murine EpiSCs
into mES-like cells requires prolonged culture and passaging in
combination with selection for mES-like cells (Bao et al., 2009).
Conversion of hLR5 Cells to a Stable Pluripotent State
Previous reports have demonstrated that, similar to our hLR5
cells, rat iPSCs and miPSCs from the NOD background are
unstable. However, NOD-derived iPSCs can be converted to
a stable, epiblast-like pluripotent state by simultaneously
removing the ectopic reprogramming factors and altering the
culture growth factor conditions (Hanna et al., 2009). We exam-
ined whether changes in the growth factor environment could
similarly induce the conversion of hLR5 cells into a stable plurip-
otent state.
Figure 4A outlines the procedure of converting hLR5 cells into
stable iPSCs. Clonal hLR5 cell lines were plated at a density of
5000 cells per cm2 in media containing human LIF and doxycy-
cline. The next day, doxycycline was withdrawn from the hLR5
cultures and cells were further maintained in the presence of
bFGF alone (Figure 4A). Withdrawal of ectopic reprogramming
factors resulted in the rapid differentiation of most of the hLR5
colonies (Figure 3A). However, after 7–10 days, stable colonies
emerged that required mechanical passaging and displayed
a typical hiPSC-like colony morphology (Figure 4B). We termed
these cells hLR5-derived human iPSCs (LD-hiPSCs). The con-
version frequency of hLR5 cells into LD-hiPSCs was approxi-
mately 0.01%, similar to the conversion of murine metastable
iPSCs into stable EpiSC-like iPSCs (Hanna et al., 2009). Pharma-
cological inhibitors of GSK3b and/or MAPK signaling were
shown to stabilize the LIF-dependent pluripotent state in iPS
and ICM-derived stem cell lines from NOD mice and rat. We
analyzed whether LIF and/or small molecule inhibitors could
positively influence the conversion of hLR5 cells (Li and Ding,
2009). Addition of LIF or the MEK inhibitor PD98059 (50 mM)
alone resulted in a slight increase in hLR5 conversion rate
(Figure S3), but in combination resulted in a near 8-fold increase
in conversion frequency compared to FGF alone. Emerging con-
verted colonies displayed the typical hiPSC morphology and
were subsequently maintained with bFGF alone, indicating that
the resulting iPSCs are not LIF dependent. Characterization of
three independent LD-hiPSC lines revealed a normal (2n = 46,
XY) karyotype of these cells (Figure 4C). ChIP analysis of
the H3K4 and H3K27 histone methylation marks at the promoter
regions of key pluripotency mediators suggested reactivation of
pluripotency genes in LD-hiPSCs (Figure S4). Indeed, Q-PCR
analysis of pluripotency regulators demonstrated reactivation
of endogenous OCT4, SOX2, NANOG, KLF4, and cMYC in
LD-hiPSCs and the absence of ectopic factors (Figure 4D). The
expression and nuclear localization of OCT4, SOX2, andNANOG
was further confirmed via immunofluorescence staining of
LD-hiPSCs (Figure 4E). LD-hiPSCs displayed a cell surface
marker profile characteristic of human pluripotent stem cells,
with expression of TRA-1-60, TRA-1-81, and SSEA4 cell surface
markers (Figure 4F), whereas the SSEA1 cell surface marker was
absent (not shown). In addition, E-Cadherin, a cell-cell interac-
tion protein that is important for pluripotent stem cell mainte-
nance and differentiation, is induced upon conversion of hLR5






Figure 4. Conversion of hLR5 Cells to a Stable Pluripotent State
(A) Schematic representation of the conversion of hLR5 cells. See also Figure S3.
(B) Representative image of the LD-hIPS colony morphology.
(C) LD-hiPSCs have a normal 46 XY karyotype.
(D) Quantitative RT-PCR analysis of the expression of endogenous pluripotency factors and the silencing of the doxycycline-inducible ectopic reprogramming
factors in two independent LD-hiPSC clones (n = 3, SD). See also Figures S4 and S5.
(E) Immunofluorescence analysis of OCT4 (top), SOX2 (middle), and NANOG (bottom) protein expression and nuclear localization in LD-hiPSCs. DAPI was used to
visualize the cell nuclei.
(F) Immunofluorescence staining of characteristic cell surface markers of human pluripotent stem cells: SSEA4 (top), TRA-1-81 (middle), and TRA-1-60 (bottom).
DAPI was used to visualize the cell nuclei.
(G) Unbiased cluster analysis of global gene expression profiles of three independent hLR5 clones, two independent LD-hiPSC clones, three human ESC lines,
and two human iPSC lines.
(H) Scatter plots of microarray data on the global gene expression patterns of hLR5 cells, human iPSCs of the same genetic background (hiPS12 [Maherali et al.,
2008]), human ESCs (HUES3), and LD-hiPSCs as indicated. The position of individual pluripotency genes listed in the legend is indicated with colored circles.
(I) Immunostaining of differentiated LD-hiPSC lines with markers for mesoderm (SMA, left), ectoderm (Tuj1, middle), and endoderm (AFP, right) as indicated.
DAPI was used to visualize cell nuclei. See also Movie S1.
(J) H&E staining of teratomas generated from clonal LD-hiPSCs. Derivatives of all three germ layers are observed: I, ganglion; II, cartilage; III, adipose tissue; IV,
gut; V, muscle; and VI, respiratory epithelium and squamous epithelium.
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human ESCs, and human iPSCs revealed that LD-hiPSCs are
highly similar to human ESCs and iPSCs, whereas hLR5 cells
form a separate cluster of unrelated cells (Figure 4G). Scatter
plots of the microarray expression analysis of hLR5 cells and
LD-hiPSCs further highlight the differences between hLR5 cells
and the genetically identical hiPS#12 cell line. In contrast, thereis high similarity between LD-hiPS and the genetically identical
hiPS#12 cell line, but also between LD-hiPS and the genetically
unrelated HUES3 human ESC line (Figure 4H; Maherali et al.,
2008). Finally, we examined the ability of LD-hiPSCs to generate
derivatives of the three embryonic germ layers. Embryoid bodies
(EBs) were generated from LD-hiPSCs and plated onto gelatin-
coated coverslips. Immunoflurescence staining revealed theCell Stem Cell 6, 535–546, June 4, 2010 ª2010 Elsevier Inc. 541
Table 1. Introduction of Transgenes into Human ESCs and hLR5 Cells by Electroporation
Experiment Cell Type
# Cells per
Electroporation # Electroporations Size of the Construct Drug Selection
Average # Colonies
per 10 3 106 Cells
#1 human ES 1 3 107 10 20 kbase hygromycin 6.8
#2 human ES 1 3 107 10 20 kbase hygromycin 10.6
#3 human ES 1 3 107 6 20 kbase hygromycin 12
#4 human ES 5 3 106 3 14 kbase puromycin 5.7
#5 hLR5 1 3 107 2 20 kbase hygromycin > > 1500
#6 hLR5 1 3 107 2 20 kbase hygromycin > > 1500
#7 hLR5 1 3 107 1 14 kbase puromycin 1300
#8 hLR5 1 3 107 1 14 kbase puromycin 1100
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Naive Human Stem Cells with Murine ESC-like Propertiespresence of cells expressing TuJ1, a neural marker, Smooth
Muscle Actin, a mesoderm lineage marker, and alpha-fetopro-
tein, a marker of endoderm differentiation (Figure 4I). In addition,
we observed that some of the EBs started beating, indicating
the development of cardiac tissue with pacemaker function
(Movie S1). Finally, subcutaneous injection of LD-hiPSCs into
immunocompromised mice resulted in the formation of tera-
tomas containing differentiated derivatives of the three embry-
onic germ layers (Figure 4J), demonstrating that the LD-hiPSCs
are indeed pluripotent.
hLR5 Cells Facilitate Transgenesis and Gene Targeting
in Human Stem Cells
A major obstacle for the application of human pluripotent stem
cells in modeling human development and disease is the diffi-
culty these cells have displayed in allowing the introduction of
foreign genetic elements (Ptaszek and Cowan, 2007). Although
such basic molecular manipulations are mainstay in mESCs,
generation of transgenic human stem cells is very inefficient
and labor intensive.
Because the human hLR5 cells display many characteristics
of murine ESCs, we examined whether these cells are more
amenable for transgene insertion by using standard electropora-
tion procedures. We tested the transfection efficiency of hLR5
cells with either a 10 kb vector constitutively expressing a
red fluorescent protein (tdTomato) and a puromycin selection
casette or a 20 kb vector expressing tdTomato driven by the
ISL1 promoter (Bu et al., 2009) and a hygromycin selection
cassette. hLR5 cells or control human ESCswere electroporated
with linearized constructs, and after antibiotic selection, the
number of colonies was counted. Table 1 summarizes the result
of 6 independent electroporations in 2 independent clonal hLR5
lines (hLR5-1 and hLR5-3) and 29 independent electroporations
of hESC lines (H9 and HUES3). Electroporation and selection of
the same number of hLR5 cells with the same amount of vector
yields more than 200-fold more colonies that had incorporated
the transgene compared to human ESC electroporation. The
high efficiency in which hLR5 cells incorporate transgenes is
particularly important when large constructs such as BAC clones
are used. Indeed, the same electroporation protocol allowed
the introduction of a 250 kb BAC clone with a puromycin selec-
tion cassette, albeit at a slightly lower efficiency, approximately
1 colony per 106 electroporated cells.
Finally, we tested the possibility of targeting specific loci in the
hLR5 cell genome. We argued that because the hLR5 cells542 Cell Stem Cell 6, 535–546, June 4, 2010 ª2010 Elsevier Inc.display many characteristics of mESCs, gene targeting may be
facilitated in these cells. We chose to target the hypoxanthine
phosphoribosyltransferase (HPRT) locus, because it offers the
benefit of both positive and negative drug selection. Cells lacking
HPRT are resistant to the drug 6-thioguanine (6-TG) but sensitive
to HAT selection, whereas wild-type cells and cells with random
integrations are HAT resistant and 6-TG sensitive. Figure 5A
shows a schematic representation of the human HPRT locus
and the targeting construct, which disrupts the second exon
by inserting a puromycin selection cassette. A combination of
three primers (indicated, Figure 5A) can be used to distinguish
between homologous recombination events and random inte-
gration of the targeting construct. Because the HPRT gene is
located on the X chromosome and therefore has only one copy
in male hLR5 cells, a single targeting event can generate a
knockout cell line. Upon electroporation of hLR5 cells with the
HPRT targeting construct, cells were treated with puromycin
to select for positive clones and subsequently treated with
6-TG to select for homologous recombination events. With this
strategy, we determined the targeting efficiency to be approxi-
mately 1% (n = 3). PCR analysis confirmed the disruption of
the wild-type gene (Figure 5B, top). In addition, we tested the
absence of functional HPRT expression in our targeted clones
by culturing the cells in the presence of HAT supplement.
As shown in Figure 5C, the HPRT knockout cells did not form
colonies in the presence of HAT supplement while they were
resistant to the positive-selection drug 6-TG.DISCUSSION
Stable and Metastable Pluripotent States
Recent reports have demonstrated that stem cells can exist in
several distinct pluripotent states, which are defined, in part,
by the culture growth factor conditions (Brons et al., 2007;
Chou et al., 2008; Tesar et al., 2007). bFGF and Activin A allow
the derivation of EpiSCs from murine postimplantation embryos
(Brons et al., 2007; Tesar et al., 2007). EpiSCs display many
characteristics of human ESCs and iPSCs, which are derived
and maintained under similar growth factor conditions. In
contrast, LIF or a combination of GSK3b and MEK inhibitors
(2i inhibitors) allows for the derivation of murine ESCs from
preimplantation blastocysts, which display a characteristic,
dome-shaped colony morphology and differ from EpiSCs in their
culture dynamics, molecular and epigenetic characteristics, and
P1 P2
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4.5 kb 4 kb
Exon 1 Exon 2 Exon 3
P1 + P2
P1 + P3










Figure 5. Homologous Recombination-Mediated Gene Targeting in hLR5 Cells
(A) Schematic representation of the human HPRT locus and the targeting construct. The PCR primers used to detect the wild-type locus and the targeting
construct (P1, P2, P3) are indicated.
(B) PCR detection of six independent clones in which the HPRT locus was successfully targeted (KO1-6) and one clone with random integration of the targeting
construct (RI). Wild-type cells (WT) were used as control. Top, presence of the wild-type allele. Bottom, detection of the targeting construct.
(C) Confirmation of functional knockout of the HPRT gene in targeted hLR5 cells. WT, wild-type; KO1 and KO2, knockout clones; RI, clone with random integra-
tion; 6-TG, 6-thioguanine; HAT, HAT supplement.
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man, 1981; Martin, 1981; Ying et al., 2008).
Yet, only a few inbred mouse strains can spontaneously give
rise to stable ESC lines, whereas other mouse strains and other
species such as rat and primates give rise only to pluripotent
stem cells with epiblast-like properties (Brons et al., 2007; Thom-
son et al., 1998; Thomson and Marshall, 1998). However, the
combineduseof LIFand2i inhibitors recentlyallowed researchers
to derive true LIF-dependent ESCs from rat blastocysts and rat
iPSCs (Buehr et al., 2008). Remarkably, in the absence of 2i inhib-
itors, these rat ESCs convert to an EpiSC-like pluripotent state
(Buehr et al., 2008). In the mouse, EpiSCs can be converted into
ESCs through the overexpression of Klf4 in the presence of 2i
inhibitors (Guo et al., 2009). The derivation of ESC-like iPSCs
from the nonpermissive NODmouse strain is similarly dependent
on either the constitutive expression of Klf4 or c-Myc or the
addition of 2i inhibitors to the culture media (Hanna et al., 2009).
It appears therefore that the EpiSC pluripotent state is the
common stable pluripotent state for most strains of mice as well
as other species, whereas the uniquemurine ESC-like pluripotent
state is ‘‘metastable’’ in these genetic backgrounds.
We found that upon iPSC reprogramming of human fibroblasts
in the presence of human LIF, colonies appear that display
hallmark characteristics of mESCs, including the dome-shaped
tightly packed mESC morphology, the high proliferation rate,
the activation of downstream targets of STAT signaling, and the
tolerance of trypsin passaging and single cell cloning. These
hLR5 cells could be derived either through direct reprogramm-
ing of primary human fibroblasts or by using a more efficient
‘‘secondary’’ fibroblast system (schematic Figure 1A). hLR5 cells
aremetastable, because they dependon the constitutive expres-
sion of ectopic reprogramming factors. Upon removal of thesefactors, hLR5 cells convert to a stable pluripotent state that is
indistinguishable from previously described hiPSC lines. The
conversion frequency of hLR5 cells into LD-hiPSCs was similar
to the frequencies of the conversion of murine metastable iPSCs
of the NOD strain into stable EpiSC-like iPSCs (Hanna et al.,
2009), about 0.01%, and is improved to almost 0.1% when LIF
and theMEK inhibitor PD98059 are added during the conversion
process. Several arguments support the notion that the emerging
LD-hiPSCs are the result of conversion of hLR5 cells into a stable
hiPSC state rather than selection of pre-existing hiPSCs in
the hLR5 population. First, the hLR5 cells were clonally derived
and maintained for more than 30 passages before conversion.
Second, the hLR5 cells were continually passaged by trypsiniza-
tion; and third, LD-hiPSCs can be derived from hLR5 cells gener-
ated directly from primary fibroblasts, which have never before
existed in a hiPSC state. In hLR5 cells, the JAK/STAT3 signaling
pathway is activated in a LIF-dependent manner, resulting in the
expression of STAT3downstream target genes. In addition, hLR5
cells respond to LIF withdrawal with changes in cell morphology
and surface marker expression. Because hLR5 cells in them-
selves do not formdifferentiated derivatives upon LIFwithdrawal,
probably because of the forced ectopic expression of the five
reprogramming factors, the cells are not LIF dependent to the
same degree as mESCs are. However, continued maintenance
of hLR5 in the presence of LIF is critical for the efficient conver-
sion of hLR5 cells into pluripotent LD-hiPSCs, in particular in
combination with the MEK inhibitor PD98059.
The conversion of hLR5 cells into hiPSCs is accompanied
by epigenetic changes at the promoter regions of critical pluripo-
tency regulators. Unexpectedly, these pluripotency factors,
although transcriptionally silent, appear to be in a ‘‘poised’’ state
in hLR5 cells, from which they can be rapidly activated. SOX2,Cell Stem Cell 6, 535–546, June 4, 2010 ª2010 Elsevier Inc. 543
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H3K27me3 histone methylation marks, which allow rapid
conversion to the transcriptionally active H3K4me3 methylation
state. OCT4, NANOG, and REX1 are silenced by H3K27me3,
yet the OCT4 promoter region is hypomethylated in the hLR5
cells, which greatly facilitates OCT4 reactivation. Similarly, the
metastable iPSCs derived from the NOD mouse strain display
hypomethylation at the Oct4 promoter (Hanna et al., 2009), sug-
gesting that demethylation of promoter regions of critical pluri-
potency regulators is an essential property of the metastable
state that allows gene reactivation and stable conversion to the
epiblast-like pluripotent state.
Interestingly, the number of ectopic factors that is required to
stabilize the mESC-like state differs between the murine NOD
strain, rat, and human. Although murine metastable NOD-iPSCs
can be maintained with the constitutive expression of a single
factor (either cMyc or Klf4) (Hanna et al., 2009), rat metastable
iPSC lines require the full complement of reprogramming factors
(Liao et al., 2009), and in the case of the hLR5 cells, this repertoire
is expanded with the addition of NANOG. Genetic background
has been shown to be a critical determinant in defining murine
(meta)stable pluripotent states (Hanna et al., 2009), and it is
possible that genetic background affects the reactivation of plu-
ripotency genes in human hLR5 cells in a similar manner.
Gene Targeting in Human Pluripotent Cells
Murine ESCs have been instrumental in the discovery of gene
function in the context of mammalian development and disease.
The standard techniques that readily allow the introduction of
transgene and reporter gene constructs in mESCs work poorly
in human pluripotent stem cells. As a result, our ability to intro-
duce foreign genetic elements into human cells is largely limited
to the use of virus or site-specific zinc-finger nucleases, which
are expensive and can have off-target effects. Recent studies
in metastable pluripotent stem cells in the NOD mouse strain
and the rat demonstrate that the LIF-dependent, mES-like
pluripotent state allows for the genetic manipulation of these
cells via standard electroporation-based techniques. We
demonstrate that in a similar fashion, large reporter constructs
and even BAC clones can be introduced into hLR5 cells. hLR5
cells even allow homologous recombination-based gene target-
ing. Until now, the (targeted) introduction of genetic elements
into human pluripotent stem cells was highly inefficient and
largely impractical. The intolerance of hESCs to grow from single
cells resulted in very low yields upon antibiotic selection and the
low proliferation rate made the process time consuming and
labor intensive. Recently, Song et al. reported a recombinant
BAC-based strategy for gene targeting in hESCs (Song et al.,
2010). Although a BAC-based system has the advantage of
high homologous recombination efficiency, the system still
suffers from the same practical difficulties associated with intro-
ducing a BAC clone into human pluripotent stem cells, the low
numbers of clones, and the added technical difficulties in identi-
fying homologous recombination events. In contrast, hLR5 cells
are tolerant to clonal selection and they have a high proliferation
rate, which further facilitates clonal outgrowth and selection.
Finally, hLR5 cells allow researchers to perform gene targeting
with small (4 kb) homologous arms via standard electroporation
procedures that have been well established for the targeting of544 Cell Stem Cell 6, 535–546, June 4, 2010 ª2010 Elsevier Inc.mESCs. Combined with the ability of hLR5 cells to convert into
a stable iPSC state, we demonstrate here that the hLR5 interme-
diate provides an efficient platform for targeted genemodification
and/or correction in human pluripotent stem cells (Figure 6). As
such, it may find use in the generation of recombinant human
cell lines forbiomedical research,drugdevelopment, andperhaps
in future cell or gene correction therapies.
EXPERIMENTAL PROCEDURES
Culture of Human ESCs and iPSCs
Human ESCs or iPSCsweremaintained on g-irradiatedMEFs in hESCmedium
(DMEM/F12 containing 20% knockout serum replacement [KOSR], 2 mM
L-glutamine, 1% NEAA, 100 U of penicillin, 100 mg of streptomycin [all from
Invitrogen], 0.1 mM b-mercaptoethanol [Sigma], and 5 ng/ml bFGF [R&D
Systems]). Cells were routinely passaged every 5–7 days. For EB derivation,
colonies were picked and collected in EB medium (IMDM containing 15%
FBS, 2mML-glutamine, 1%NEAA, 1mM sodium pyruvate, 100 U of penicillin,
100 mg of streptomycin [all from Invitrogen], 200 mg/mL iron-saturated trans-
ferrin [Sigma], 4.5 mM monothioglycerol [Sigma], and 50 mg/mL ascorbic
acid [Sigma]). Colonies were cultured with gentle agitation. After 7–9 days,
colonies were transferred to gelatin-coated chamber slides, allowed to
adhere, and incubated for 3–5 more days. For teratoma formation, LD-hiPSCs
were injected subcutaneously into NOG mice (Jackson Laboratories, Bar
Harbor, ME) in accordance with institutional guidelines and approval. After
10–12 weeks, teratomas were dissected, washed, and fixed. Parafin
sections were stained with H&E.
Derivation and Maintenance of hLR5 Cells
Clone#12 hiPSC colonies were differentiated as described (Maherali et al.,
2008). The fibroblasts were induced to generate hLR5 cells by passaging the
cells onto MEF feeders in hLR5 media (DMEM/F12 containing 20% KOSR,
100 U of penicillin, 100 mg of streptomycin, 2 mM L-glutamine, 1% NEAA [all
from Invitrogen], 0.1 mM b-mercaptoethanol [Sigma], 10 ng/ml human LIF
[Sigma], and 2 ng/ml doxycycline [Sigma]). Emerging colonies were individu-
ally picked and subcultured by trypsin digest in hLR5 media on MEF feeders.
For the direct reprogramming of human fibroblasts (HS27, ATCC) into hLR5
cells, 105 cells per 1 cm2 were transduced with the STEMCCA lentivirus (con-
taining doxycycline-inducible humanOCT4, SOX2, KLF4, and cMYC) and rtTA
with or without a doxycycline-inducible lentivirus for NANOG (Maherali et al.,
2008; Sommer et al., 2009; Stadtfeld et al., 2008). After approximately
30 days, emerging colonies were individually picked and expanded further
by trypsin digest in hLR5 media with MEF feeders. hLR5 cells are passaged
every 2–3 days, depending on culture density.
Microarray and Q-PCR Analysis
Total RNA was extracted with Trizol (Invitrogen) according to the manufac-
turer’s protocol. cDNA synthesis (Superscript III First-Strand synthesis
system, Invitrogen) was performed with random primers. qRT-PCRs were
carried out with Brilliant II SYBR Green mix (Stratagene) and a Stratagene
MXPro4000 real-time thermocycler. Primer sequences for the analysis of
endogenous and ectopic pluripotency gene expression were reported previ-
ously (Maherali et al., 2008).
For genome-wide expression analysis, total RNA was labeled and hybrid-
ized to Agilent Whole Human Genome Oligo 4X44K Microarrays (one-color
platform) according to the manufacturer’s protocols. The gene expression
results were analyzed with GeneSifter microarray analysis software.
FACS Analysis
Cells were incubated with the antibodies against the indicated surface anti-
gens for 30 min at 4C in RPMI + 0.5% FBS. The following antibodies were
used for cell surface marker profiling: SSEA1 (BD Biosciences), TRA-1-81,
TRA-1-60, SSEA3, and SSEA4 (Millipore). Cells were washed twice and incu-
bated with the relevant fluorphore-conjugated secondary antibody (BD Biosci-
ences) for 30min at 4C. Cells were washed, resuspended in RPMI/0.5% FBS,





























Figure 6. Application of the Intermediate hLR5 State to Generate Recombinant Human Pluripotent Stem Cells for Research, Drug Develop-
ment, and Potential Gene Correction Therapy
Schematic model summarizing the procedure for gene targeting in human (patient) cells via the metastable hLR5 intermediate state. Human primary fibroblasts
are collected and transduced with the five reprogramming factorsOCT4, SOX2, NANOG, KLF4, and cMYC. Upon induction of reprogramming in the presence of
human LIF, hLR5 colonies emerge. hLR5 cells are genetically modified via standard. The modified hLR5 cells are subsequently converted into pluripotent
LD-hiPSCs, which in turn can be used in research or differentiated for use in future cell/gene correction therapies.
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Cellswere trypsinized, strained, resuspended in700ml PBScontaining15–30mg
linearizedDNA,and transferred toa0.4cmgapelectroporationcuvette (Biorad).
Theelectroporationwascarriedoutwitha single 320V, 200mFpulse.Uponelec-
troporation, cells were replated onto gelatinized dishes with DR4MEFs. Antibi-
oticselectionwasstarted48–72hr laterwitheither 25mg/ml hygromycin (Invitro-
gen) or 0.25 mg/ml puromycin (Invivogen) as indicated. ForHPRTKO, cells were
selected with puromycin followed by treatment with 6-thioguanine (6-TG,
Sigma) to select for homologous recombinants. HAT selection was carried out
by adding 13 HAT supplement (Invitrogen) directly to the hLR5 medium.
ChIP
Cells were fixed in 1% formaldehyde for 10 min, quenched with glycine, and
washed three times with PBS. Cells were then resuspended in lysis buffer
and sonicated 103 30 s in a Bioruptor (Diagenode, Philadelphia, PA) to shear
the chromatin to an average length of 600 bp.
Supernatants were precleared with protein-A agarose beads (Roche, Man-
nheim, Germany) and 10% input was collected. Immunoprecipitations were
performed with polyclonal antibodies to H3K4trimethylated, H3K27trimethy-
lated, and normal rabbit serum (Upstate, Temucula, CA). DNA-protein com-
plexes were pulled down with Protein-A agarose beads and washed. DNA
was recovered by overnight incubation at 65C to reverse cross-links and puri-
fied with QIAquick PCR purification columns (QIAGEN, Maryland). Enrichment
of the modified histones in different genes was detected by quantitative real-
time PCR with the primers in the Supplemental Experimental Procedures
(Table S1).
Immunostaining
Primary antibodies used were: a-TRA-1-60, a-SSEA-3, a-SSEA-4, a-TRA-1-
81, a-Sox2 (all from Millipore), a-SSEA1, a-Stat3 (both from Cell Signaling),a-Oct4, a-Nanog (both from Abcam), a-TuJ1 (Covenance), a-SMA (Sigma),
and a-AFP (Santa Cruz). All secondary antibodies were from Invitrogen.
The nuclei were visualized with DAPI.
Western Blotting
Cells were lysed with RIPA buffer containing proteinase inhibitors. The protein
concentration was estimated with Bradford reagents and equal amounts of
protein were run on 4%–12% Bis-Tris Gels (Invitrogen) and transferred to
PVDF membranes (Millipore). Primary antibodies used were: Phospho-Stat3,
Stat3, E-Cadherin (all Cell Signaling), and Tubulin (Sigma). HRP-coupled
secondary antibody was from Cell Signaling.
ACCESSION NUMBERS
Microarray data have been deposited in the GEO database with the accession
number GSE21792.
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